PATENT CLAIM ANALYSIS

Application Number: 16089990
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["514", "04400A"]

Abstract:
A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.

Claim (Index 21):
The composition of  claim 20 , wherein said inhibitor is formulated for intravitreal injection.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 97.0
- Lexical Diversity: 1.08696
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14237082', '12999746', '15118667', '12803118', '12510201']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7692302390087663
- 35 USC 102 Novelty (BERT): 0.5178068732066227
- Combined Prediction Score: 0.744087902428552
- Mean Citation Score: 223.07821
- Max Citation Score: 270.5101
- Similarity Product: 161.9418652531028

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test